NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

OS compared to placebo was also a confounded endpoint, because, ironically, DCVax-l can also offer help after recurrence when Temodar therapy is stopped and DCVax-l therapy begins.

The two as yet unpublished remaining endpoints of interest are confirmed progression and tumor response, imo.

I am anticipating at least some tumor response, as they added that endpoint in 2019/2020, Dr. Ashkan can be seen in a news clip explaining no residual tumor in his patient after three years since surgery, and studies extraneous to NWBO have shown occasional slowly evolving tumor responses (shrinkage) in autologous DC therapy settings.

If there is tumor response, it would be another internal control signal.